News | July 04, 2023
Biocon Biologics' Hulio Biosimilar to Humira now available in the US
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
The company is already marketing the 4 mg and 10 mg strengths
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Subscribe To Our Newsletter & Stay Updated
